Skip to main content
SpringerLink
Log in

Elbasvir/Grazoprevir: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic HCV genotype 1 or 4 infection. This article summarizes the milestones in the development of elbasvir/grazoprevir leading to this first global approval for chronic HCV genotype 1 or 4 infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Food and Drug Administration. FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 [media release]. 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm. Accessed 9 Feb 2016.

  2. Merck & Co Inc. Zepatier™ (elbasvir and grazoprevir) tablets, for oral use: US prescribing information. 2016. http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed 2 Feb 2016.

  3. Merck. Merck receives approval of ZEPATIER™ (elbasvir/grazoprevir) in Canada for the treatment of chronic hepatitis C for patients with genotype 1, 3, or 4 infection following priority review [media release]. 2016. http://www.merck.ca/Assets/News/Merck%20Canada%20Press%20Release%20-%20ZEPATIER%20Launch%20-%20FINAL%20-%20Feb%203%202016%20-%20EN.pdf. Accessed 9 Feb 2016.

  4. Merck & Co Inc. MSD provides update on European Medicines Agency Marketing Authorization Application for investigational chronic hepatitis C therapy elbasvir/grazoprevir [media release]. 2015. http://www.merck.com. Accessed 9 Feb 2016.

  5. Yeh WW, Caro L, Guo Z, et al. Pharmacokinetics of co-administered HCV protease inhibitor MK-5172 and NS5A inhibitor MK-8742 in volunteers with end-stage renal disease on haemodialysis or severe renal impairment not on haemodialysis [abstract no. 1940]. Hepatology. 2014;60(Suppl 1):1137A.

    Google Scholar 

  6. Yeh WW, Feng HP, Dunnington KM, et al. No clinically meaningful pharmacokinetic interactions between HCV inhibitors grazoprevir/elbasvir with tacrolimus, mycophenolate mofetil, and prednisone, but cyclosprine increases grazoprevir/elbasvir exposures in healthy subjects [abstract no. 725]. Hepatology. 2015;62(Suppl 1):570A–1A.

    Google Scholar 

  7. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97.

    Article  CAS  PubMed  Google Scholar 

  8. Kawada N, Suzuki F, Karino Y, et al. Efficacy, safety and pharmacokinetics of grazoprevir (MK-5172) and elbasvir (MK-8742) in hepatitis C genotype 1 infected non-cirrhotic Japanese patients (phase 2 portion in phase 2/3 combined study) [abstract no. 707]. Hepatology. 2015;62(Suppl 1):559A.

    Google Scholar 

  9. Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis [abstract no. P049]. Transpl Int. 2015;28(Suppl 2):31–2.

    Google Scholar 

  10. Vierling JM, Kugelmas M, Lawitz E, et al. Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection [abstract no. P0769]. J Hepatol. 2015;62(Suppl 2):618.

    Article  Google Scholar 

  11. Kwo P, Gane E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir +/− RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE Treatment-Experienced trial [abstract no. P0886]. J Hepatol. 2015;62(Suppl 2):S674–5.

    Article  Google Scholar 

  12. Dore G, Altice F, Litwin AH, et al. C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy [abstract no. 40]. Hepatology. 2015;62(Suppl 1):227A–8A.

    Google Scholar 

  13. Poordad F, Lawitz E, Gutierrez JA, et al. C-SWIFT: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks [abstract no. O006]. J Hepatol. 2015;62(Suppl 2):S192–3.

    Article  Google Scholar 

  14. Lawitz E, Poordad F, Gutierrez JA, et al. C-SWIFT retreatment (Part B): 12 weeks of elbasvir/grazoprevir with sofosbuvir and ribavirin successfully treated GT1-infected subjects who failed short-duration all-oral therapy [abstract no. LB-12]. Hepatology. 2015;62(6):1386A–7A.

    Google Scholar 

  15. Brown A, Hezode C, Zuckerman E, et al. C-SCAPE: efficacy and safety of 12 weeks of grazoprevir +/− elbasvir +/− ribavirin in patients with HCV GT2, 4, 5 or 6 infection [abstract no. P0771]. J Hepatol. 2015;62(Suppl 2):S619.

    Article  Google Scholar 

  16. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–86.

    Article  CAS  PubMed  Google Scholar 

  17. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564–72.

    Article  CAS  PubMed  Google Scholar 

  18. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32–6.

    Article  PubMed  Google Scholar 

  19. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–45.

    Article  CAS  PubMed  Google Scholar 

  20. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.

    Article  PubMed  Google Scholar 

  21. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.

    Article  PubMed  Google Scholar 

  22. Merck & Co Inc. Merck’s pivotal phase 3 C-EDGE program evaluating grazoprevir/elbasvir shows high sustained virologic responses across broad range of patients with chronic hepatitis C virus infection [media release]. 2015. http://www.mercknewsroom.com/news-release/hepatitis-c-newsroom/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevirelbasv. Accessed 10 Feb 2016.

  23. Merck & Co Inc. Merck announces presentation of phase 3 results of investigational elbasvir/grazoprevir in people with chronic hepatitis C genotypes 1, 4 or 6 infection who inject drugs and are on opioid agonist therapy [media release]. 2015. http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-presentation-phase-3-results-investigatio. Accessed 10 Feb 2016.

  24. Merck & Co Inc. Merck announces presentation of phase 2 clinical trial results of investigational chronic hepatitis C therapy grazoprevir/elbasvir at the International Liver Congress™ 2015 [media release]. 2015. Accessed 10 Feb 2016.

  25. Dusheiko GM, Manns MP, Vierling JM, et al. Safety and tolerability of grazoprevir/elbasvir in patients with chronic hepatitis C (HCV) infection: integrated analysis of phase 2–3 trials [abstract no. 712]. Hepatology. 2015;62(Suppl 1):562A.

    Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of elbasvir/grazoprevir was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Gillian Keating is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M. Elbasvir/Grazoprevir: First Global Approval. Drugs 76, 617–624 (2016). https://doi.org/10.1007/s40265-016-0558-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0558-3

Keywords

Search

Navigation